Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- Procedure: Mastectomy with sentinel lymph node biopsy
- Registration Number
- NCT05961280
- Lead Sponsor
- Gangnam Severance Hospital
- Brief Summary
This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 385
- Women diagnosed with DCIS in preoperative biopsy samples obtained by core needle biopsy, vacuum-assisted breast biopsy, or excisional biopsy
- Women underwent curative surgery for DCIS
- Patients who received breast-conserving surgery
- Patients who had concurrent contralateral invasive breast cancer
- Patients who were in case of ipsilateral breast tumor recurrence
- Patients whose invasiveness was uncertain in the biopsy samples
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description DCIS Mastectomy Mastectomy with sentinel lymph node biopsy Patients who undergo mastectomy with sentinel lymph node biopsy for DCIS at biopsy
- Primary Outcome Measures
Name Time Method Axillary lymph node metastasis rate up to 2 weeks after surgery Our primary objective was to identify the axillary lymph node metastasis rate in patients with DCIS at diagnosis who underwent mastectomy with axillary surgery.
- Secondary Outcome Measures
Name Time Method